Skip to main content
. 2023 Feb 24;26(3):106267. doi: 10.1016/j.isci.2023.106267

Figure 5.

Figure 5

Comparison of microglia phagocytic capacity of ALS-PDC-affected and ALS-PDC-unaffected neuronal network

(A) Microglia derived from ALS-PDC-affected iPSCs displayed reduced uptake of HiLyte Fluor 488-labeled beta-amyloid (1–40). BMAA treatment upregulated beta-amyloid uptake in ALS-PDC-unaffected microglia, but impaired that of microglia derived from ALS-PDC affected iPSCs.

(B) Quantification of microglia phagocytosis in ALS-PDC-affected, -unaffected and BMAA treated samples. The data were analyzed using the Student’s t test in GraphPad Prism 8. All values were compared to the ALS-PDC-unaffected condition and expressed as means ± SEM. ∗p< 0.05, ∗∗p< 0.01. ∗∗∗p< 0.001,∗∗∗∗p< 0.0001.